Compare FMBH & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMBH | PCRX |
|---|---|---|
| Founded | 1865 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 951.4M | 1.0B |
| IPO Year | 1995 | 2010 |
| Metric | FMBH | PCRX |
|---|---|---|
| Price | $40.04 | $22.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $43.40 | $35.33 |
| AVG Volume (30 Days) | 85.3K | ★ 761.1K |
| Earning Date | 04-30-2026 | 05-15-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | 16.06 | ★ 107.44 |
| EPS | ★ 3.83 | 0.16 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | $9.38 | $9.77 |
| Revenue Next Year | $6.55 | $9.71 |
| P/E Ratio | ★ $10.47 | $137.50 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $27.58 | $18.80 |
| 52 Week High | $44.85 | $27.99 |
| Indicator | FMBH | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 37.30 | 49.39 |
| Support Level | $34.26 | $20.41 |
| Resistance Level | $41.40 | $23.82 |
| Average True Range (ATR) | 1.32 | 0.97 |
| MACD | -0.38 | -0.02 |
| Stochastic Oscillator | 19.93 | 50.80 |
First Mid Bancshares Inc is a United States based financial holding company. Through its wholly-owned subsidiary, First Mid Bank, it is engaged in the business of banking. The Company offers trust, farm services, investment services, and retirement planning through its wholly owned subsidiary, it also provides data processing services to affiliates and insurance products and services to customers through its subsidiary. The company's operations cover community banking, wealth management and insurance services. Key revenue is derived from the provision of community banking services.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.